Introduction ImmunoGen is a company that specializes in the development of antibody-based cancer treatments. They use their Targeted Antibody Payload (TAP) technology to deliver a powerful cytotoxic agent to cancer cells. Some of their products include Trastuzumab-DM1, IMGN901, SAR3419, and IMGN388. ImmunoGen has partnerships with various pharmaceutical companies and has been in business since 1981. They are headquartered in Waltham, Massachusetts. |
Disease Domain | Count |
---|---|
Neoplasms | 18 |
Hemic and Lymphatic Diseases | 6 |
Immune System Diseases | 3 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 12 |
Monoclonal antibody | 4 |
Small molecule drug | 1 |
Radiolabeled antibody | 1 |
Antibody Fragment-Drug Conjugates (FDCs) | 1 |
Target |
Mechanism FOLR1 antagonists [+1] |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date14 Nov 2022 |
Target |
Mechanism CD19 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CD123 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Sep 2024 |
Sponsor / Collaborator |
Start Date18 Dec 2023 |
Sponsor / Collaborator |
Start Date03 Oct 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mirvetuximab soravtansine ( FOLR1 x Tubulin ) | Primary peritoneal carcinoma More | Phase 3 |
Coltuximab ravtansine ( CD19 x Tubulin ) | Acute Lymphoblastic Leukemia More | Phase 2 |
IMGC-936 ( ADAM9 x Tubulin ) | Advanced Malignant Solid Neoplasm More | Phase 1/2 |
Eramkafusp alfa ( CD20 x IFNAR ) | Non-Hodgkin Lymphoma More | Phase 1 |
Pivekimab ( CD123 ) | Hematologic Neoplasms More | Clinical |